Measurement of Early Bone Loss Around a Total Hip Arthroplasty
NCT ID: NCT01046019
Last Updated: 2011-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23 participants
OBSERVATIONAL
2007-09-30
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bone Mineral Density Changes of the Acetabulum After Revision Hip Arthroplasty Using Bone Impaction Grafting
NCT02061904
Consequence of the Learning Curve in Direct Anterior Approach for Total Hip Replacement
NCT02645435
Analysis of Defined Elements on DXA in Patients Undergoing Hip Arthroplasty
NCT06324708
The Clinical Outcomes After Direct Anterior Approach and Microposterior Approach for Total Hip Arthroplasty
NCT03210844
CT for Diagnosis of Implant Stability in Revision Arthroplasty
NCT00367289
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We included 23 patients operated with total hip prosthesis (THP). They were measured with DXA at 1, 5 and 14 days, 3 and 12 months after the operation. Results were given in percent (+/-SD) for each Gruen zone. There were no changes in bone density between the first 3 measurements. In all zones, except zone 1, the lowest BMD was measured after 3 months. We concluded that DXA measurements done within 14 days after the operation can be used as reference measurements for later follow ups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* dementia
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ullevaal University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oslo University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lars Nordsletten, Professor
Role: STUDY_DIRECTOR
Ullevaal University Hospital
Berte G Bøe, MD
Role: PRINCIPAL_INVESTIGATOR
Ullevaal University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35-07122b 1.2007.896
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.